Talaris Therapeutics
Corporate Office
93 Worcester Street
Suite 120
Wellesley
MA
02481
United States
Website: https://talaristx.com/
Email: info@talaristx.com
About Talaris Therapeutics
Who We Are
Talaris Therapeutics, Inc. is a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders.
Our Mission
To bring our transformative cell therapies to patients as quickly and safely as possible.
Our Vision
To transform the standard of care for solid organ transplant recipients and people living with severe immune and blood disorders.
Our Team and Values
Joining Talaris is an opportunity to use your talents to make a difference in patients’ lives. Together, we seek to be empowered, compassionate, energized and revolutionary. These values represent how we think about our work for our patients, how we collaborate as colleagues, and how we set our own direction as individuals within the Talaris team.
We set high standards for ourselves, and we work hard to achieve them with a collaborative culture where every member plays a role.
Our Locations
We maintain corporate offices in Boston, MA, a GMP cell processing facility in Louisville, KY, and research and development laboratories in Houston, TX.
Corporate Office
93 Worcester Street
Suite 120
Wellesley, MA 02481
Cell Processing Facility & Corporate Office
570 S. Preston St., Suite 400
Louisville, KY 40202
Research and Development
9940 W. Sam Houston Parkway,
Suite 300
Houston, TX 77099
59 articles with Talaris Therapeutics
-
Talaris Therapeutics is cutting one-third of its workforce and dropping two clinical trials studying its lead candidate.
-
Talaris Therapeutics Announces Plans to Explore Strategic Alternatives and Implements Restructuring Plan
2/16/2023
Talaris Therapeutics, Inc., announced that it has completed a review of its business and program prospects.
-
Talaris Therapeutics to Participate at the 5th Annual Evercore ISI HealthCONx Conference
11/22/2022
Talaris Therapeutics, Inc. today announced that Scott Requadt, Chief Executive Officer of Talaris, will participate in a fireside chat at the 5th Annual Evercore ISI HealthCONx Conference being held virtually on Tuesday, November 29, 2022 at 4:20 PM ET.
-
Talaris Therapeutics Announces Third Quarter 2022 Financial Results and Corporate Update
11/10/2022
Talaris Therapeutics, Inc. reported financial results for the three- and nine-month periods ended September 30, 2022 and provided an update on its business.
-
Talaris Therapeutics Presents Data on Mechanisms of FCR001 Activity to Induce Immune Tolerance
11/7/2022
Talaris Therapeutics, Inc. presented new data characterizing the mechanisms of FCR001-induced immune tolerance in two oral presentations at the 2022 American Society of Nephrology (ASN) Annual Meeting.
-
Talaris Therapeutics Provides Update on FREEDOM-1 Phase 3 Clinical Trial
10/20/2022
Talaris Therapeutics, Inc. today announced a status update on its Phase 3 FREEDOM-1 study in living donor kidney transplant (LDKT) recipients.
-
After the Data Monitoring Committee reviewed the case based on protocol modifications implemented earlier this year, it was determined that enrollment in the trial and dosing may continue.
-
Talaris Therapeutics Announces Upcoming Presentations at American Society of Nephrology Annual Meeting
10/17/2022
Talaris Therapeutics, Inc. today announced upcoming data presentations at the American Society of Nephrology (ASN) Annual Meeting, taking place November 3-6, 2022 in Orlando, Fla.
-
Talaris Therapeutics to Present at the 2022 Cell & Gene Meeting on the Mesa
10/4/2022
Talaris Therapeutics, Inc. today announced that Scott Requadt, Chief Executive Officer of Talaris, will present at the 2022 Cell & Gene Meeting on the Mesa being held October 11-13, 2022 in Carlsbad, California.
-
Talaris Therapeutics Presents Additional Phase 2 Data and Analyses at American Transplant Congress 2022
6/7/2022
Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, presented additional data and analyses from its Phase 2 trial of FCR001 and other studies of its Facilitated Allo-HSCT Therapy platform at the 2022 American Transplant Congress (ATC).
-
Talaris Therapeutics Announces Conference Call to Highlight Presentations at the American Transplant Congress (ATC) and Provide a Data Update from its Phase 3 FREEDOM-1 Study
6/1/2022
Talaris Therapeutics, Inc. announced it will host a conference call to discuss its presentations at the American Transplant Congress and provide a data update from its ongoing Phase 3 FREEDOM-1 study in living donor kidney transplant recipients.
-
Talaris Therapeutics to Present at the Jefferies Healthcare Conference
5/31/2022
Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that Scott Requadt, Chief Executive Officer of Talaris, will present at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 10:30 AM ET at the Marriott Marquis in New York, NY.
-
Talaris Therapeutics to Present at the H.C. Wainwright Global Investment Conference
5/17/2022
Talaris Therapeutics, Inc. announced today announced that Scott Requadt, Chief Executive Officer of Talaris, will be presenting virtually at the H.C. Wainwright Global Investment Conference being held May 23-25, 2022.
-
Talaris Therapeutics Announces Changes to Board of Directors
5/17/2022
Talaris Therapeutics, Inc. announced the appointment of independent director Karen Smith, M.D., Ph.D., MBA, LLM to the Company’s Board of Directors.
-
Talaris Therapeutics Announces First Quarter Financial Results and Corporate Update
5/12/2022
Talaris Therapeutics, Inc. reported financial results for the three-month period ended March 31, 2022, and provided an update on its business.
-
Clinical Catch-Up: COVID-19, AAN, ACC
4/11/2022
It was a very busy week for clinical trial news, in part because of presentations coming out of the American Academy of Neurology (AAN) meeting. Here’s a look. -
Global health officials are monitoring COVID-19 cases with an eye to identifying the emergence of new, potentially more deadly or more infectious variants. Read on for more details.
-
Talaris Therapeutics Presents Data on COVID-19 Outcomes Among Kidney Transplant Patients Treated with FCR001
4/6/2022
Talaris Therapeutics, Inc. (Nasdaq: TALS), today shared new data on COVID-19 outcomes among living donor kidney transplant (LDKT) patients treated in the Company’s Phase 2 trial of investigational cell therapy product FCR001 (NCT00497926).
-
Talaris Therapeutics to Participate at Two Upcoming Investor Conferences - Mar 22, 2022
3/22/2022
Talaris Therapeutics, Inc. announced that members of its senior management team will participate at the following investor conferences:
-
Talaris Therapeutics Announces Fourth Quarter and Year-End Financial Results
3/17/2022
Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune disorders, today reported financial results for the quarter and year ended December 31, 2021, and provided an update on its business.